{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T11:13:55Z","timestamp":1722510835588},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OPTH"],"DOI":"10.2147\/opth.s90979","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T01:48:16Z","timestamp":1446169696000},"page":"2027","source":"Crossref","is-referenced-by-count":2,"title":["Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity"],"prefix":"10.2147","author":[{"given":"Jo\u00e3o","family":"Filho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odalis","family":"Ar\u00e1mbulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Dib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Iturralde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahir","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,10]]},"container-title":["Clinical Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=27760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:58:46Z","timestamp":1477868326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/intravitreal-ranibizumab-as-a-primary-or-anbspcombined-treatment-for-s-peer-reviewed-article-OPTH"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/opth.s90979","relation":{},"ISSN":["1177-5483"],"issn-type":[{"value":"1177-5483","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}